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Abstract
The development of multidrug resistance (MDR) limits the efficacy of continuous chemotherapeutic treatment in chronic
myelogenous leukemia (CML). Low molecular weight protein tyrosine phosphatase (LMW-PTP) is up-regulated in several
cancers and has been associated to poor prognosis. This prompted us to investigate the involvement of LMW-PTP in MDR.
In this study, we investigated the role of LMW-PTP in a chemoresistant CML cell line, Lucena-1. Our results showed that
LMW-PTP is highly expressed and 7-fold more active in Lucena-1 cells compared to K562 cells, the non-resistant cell line.
Knocking down LMW-PTP in Lucena-1 cells reverted chemoresistance to vincristine and imatinib mesylate, followed by
a decrease of Src and Bcr-Abl phosphorylation at the activating sites, inactivating both kinases. On the other hand,
overexpression of LMW-PTP in K562 cells led to chemoresistance to vincristine. Our findings describe, for the first time, that
LMW-PTP cooperates with MDR phenotype, at least in part, through maintaining Src and Bcr-Abl kinases in more active
statuses. These findings suggest that inhibition of LMW-PTP may be a useful strategy for the development of therapies for
multidrug resistant CML.
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Introduction
Failure of cancer chemotherapy may occur due to increased
efflux of chemotherapeutic agents, leading to reduction of
intracellular drug levels and consequent drug insensitivity, often
to multiple agents. A well-established cause of multidrug resistance
(MDR) involves increased expression of members of the ATP-
binding cassette (ABC) transporter superfamily, which extrude
various chemotherapeutic compounds from cells. In this context,
resistance to chemotherapy is a major drawback in the effective
treatment of chronic myelogenous leukemia (CML). Although
initially most cases react favourably to chemotherapy, the build-up
of resistance remains a major problem [1], [2]. Therefore, the
identification of new processes involved in cancer resistance may
open a new avenue to improve chemotherapy.
Low Molecular Weight Protein Tyrosine Phosphatases (LMW-
PTP) are a family of enzymes related to various cellular events,
such as cytoskeleton rearrangement, cell growth and modulation
of immune response [3], [4]. Overexpression of LMW-PTP has
been reported in several tumors and is generally associated with
a proliferative phenotype and poor prognosis [5]. The LMW-PTP
family has been reported to interact with several tyrosine kinases
including PDGF [6], JAK2 [7], STAT5 [8], Insulin receptor, Eph
Receptor [9] and EGF receptor [10]. However, the role of LMW-
PTP in CML has not yet been well characterized.
In this study we report for the first time the contribution of
LMW-PTP in the maintenance of chronic myeloid leukemia
chemoresistance. We used the erythroleukemia cell line K562 and
its resistant counterpart Lucena-1, which displays a high expres-
sion of the ABC-transporter P-glycoprotein (P-gp). We observed
that LMW-PTP is overexpressed and highly active in Lucena-1
cells. Furthermore, overexpression of LMW-PTP in K562 cells
impaired vincristine-induced cell death. On the other hand, knock
down of LMW-PTP sensitizes Lucena-1 cells to vincristine (VCR),
suggesting a causal role for LMW-PTP in resistance.
Materials and Methods
Cell line and Reagents
K562 cells were purchased from the American Type Culture
Collection (ATCC, Rockville, MD) and the resistant cell line
Lucena-1 was produced as described previously [11]. Anti-sheep,
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anti-rabbit, anti-goat and anti-mouse peroxidase-conjugated anti-
bodies were purchased from Cell Signaling Technology (Beverly,
MA). Antibodies against GAPDH and b-actin were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). LMW-PTP
(ACP1) antibody was obtained from Abcam. Src, p-Src, FAK, p-
FAK and p-c-ABL antibodies were purchased from Cell Signaling.
Monoclonal anti-P-glycoprotein (MDR) Clone F4, (Mouse Ascites
Fluid, Product No. P 7965) was from Sigma. Caspase 3 kit assay
from R & D Systems.
Cell Culture
K562 and Lucena-1 cells were routinely grown in suspension in
RPMI 1640 medium supplemented with 2 mM glutamine,
100 U/mL penicillin, 100 mg/ml streptomycin and 10% heat-
inactivated fetal bovine serum, at 37uC in a 5% CO2 humidified
atmosphere. VCR 60 nM was routinely added to Lucena-1
culture medium [11].
Cell Viability
Cells were plated at 16105 cells/mL and treated with VCR or
imatinib mesylate for 24 h. After treatment, cell viability was
assessed by trypan blue dye exclusion [12].
Phosphatase activity
To quantify the phosphatase activity, cells were lysed with
200 mL of Lysis Buffer (20 mM HEPES, pH 7,7 with 2,5 mM
MgCl2, 0,1 mM EDTA, 20 mM p-nitrofphenilphosphate, 1 mM
O-vanadate, 1 mM PMSF, 1 mM DTT, 10 mg/mL aprotinin e
10 mg/mL leupeptin) on ice for 2 h. After clarifying by centrifu-
gation, the cell extract was incubated with antibodies against
LMW-PTP overnight at 4uC under rotation. Later, A-Sepharose
Protein was added to cell homogenate and incubated for 2 h at
4uC. The cell extract was washed 3 times with lysis buffer and 2
times with acetate buffer 100 mM pH5.5. The precipitate was
ressuspended in acetate buffer 100 mM pH 5.5 and immediately
was used for enzymatic assay.
PTP activity was measured using the Protein Tyrosine
Phosphatase Assay kit Non Radioactive from Sigma (St. Louis,
MO). Briefly, reaction medium contained 80 mM Acetate Buffer
pH5.5, and 0.2 mM of PTP phosphorylated substrate. The
reaction was carried at 37uC for 20 min and stopped with an
equal volume of Malachite Green/AmmoniumMolybdate reagent
(1:100). The amount of phosphate produced in the reaction was
measured at 650 nm, in a microplate reader (ELx 800 BIO-TEK),
and compared to a standard curve.
Western Blotting Analysis
Cells (36107) were lysed in 200 mL of lysis buffer (50 mM Tris–
HCl pH 7.4), 1%Tween 20, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM EGTA, 1 mM Na3VO4, 1 mM NaF and protease
inhibitors (1 mg/ml aprotinin, 10 mg/ml leupeptin, and 1 mM4-(2-
aminoethyl) benzenesulfonyl-fluorid-hydrochloride)] for 2 h on ice.
Protein extracts were cleared by centrifugation and protein
concentrations were determined using the Lowry method. Twice
the volume of SDS gel loading buffer (100 mM Tris–HCl pH 6.8),
200 mMDTT,4%SDS,0.1%bromophenolblueand20%glycerol)
was added to the samples, whichwere subsequently boiled for 5 min.
Cell extracts were resolved by SDS-polyacrylamide gel (12%)
electrophoresis (PAGE)andtransferredtonitrocellulosemembranes.
Membranes were blocked in 5% fat-free dried milk or bovine serum
albumin in Tris-buffered saline-Tween 20 (0.1%) and incubated
overnight at 4uC with the appropriate primary antibody at 1:1000
dilution. After washing in TBS-Tween 20 (0.1%), membranes were
incubated with anti-rabbit, anti-mouse and anti-goat horseradish
peroxidase-conjugated secondary antibodies, at 1:5000 dilutions, in
blocking buffer for 1 h. Proteins were detected using enhanced
chemiluminescence.
Transfection of K562 Cells with LMW-PTP Plasmid
K562 cells (100.000 cells/mL) were grown for 24 h and the
transfections were done using the Effectene transfection kit
(QIAGEN Benelux, Venlo, Netherlands) according to the
manufacturer’s instructions. Briefly, the cells were transfected
with 2.4 mg of pcDNA3.1/V5-His-TOPO vector with or without
an insert containing the sequence of human LMW-PTP after
a cytomegalovirus promoter. Overexpression was always verified
by Western blotting.
Transfection of K562 and Lucena-1 Cells with LMW-PTP
siRNA
Lucena-1 cells (100.000 cells/mL) were grown for 24 h and
subsequently transiently transfected with LMW-PTP siRNA
(Qiagen cat.# SI02776851). Transfections were done using the
Hiperfect transfection kit (QIAGEN Benelux, Venlo, Netherlands)
according to the manufacturer’s instructions. Briefly, the cells were
transfected with LMW-PTP siRNA (final concentration: 5 nM) for
72 h, and then washed with Phosphate Buffer Saline and lysed
with a specific buffer for Western blotting procedure. Lysates were
subsequently mixed with loading buffer for electrophoresis. The
efficiency of transfection was assessed based on the expression of
LMW-PTP by Western blotting analysis.
Caspase 3 Activity Assay
After silencing procedure the Lucena-1 was treated with VCR
or imatinib for 24 h. Afterwards, the cells were centrifuged and
washed with PBS. Caspase activity was determined by the
measurement at 405 nm of p-nitroaniline released from the
cleavage by caspase 3 (Ac-DEVD-pNA) substrates, according to
manucfaturers instructions (R & D Systems). The enzyme activity
was expressed in pmol/mL/min and the extinction coefficient of
pNA was 10,000 M21 cm21.
P-Glycoprotein Activity Evaluation
To measure P-gp activity we used Rhodamine 123, one of its
substrates. After silencing LMW-PTP, cells were incubated with
200 ng/mL Rhodamine 123 for 30 minutes with or without a P-
gp inhibitor (5 mM verapamil). Afterwards, cells were washed with
Phosphate Buffer Saline and incubated in culture media with or
without P-gp inhibitor for 1 h at 37uC, washed and suspended in
cold PBS and kept on ice. Rhodamine fluorescence was sub-
sequently assessed by flow cytometry analysis within the live-gate,
using a FACScalibur (Becton and Dickinson, USA). Data were
analyzed in the WinList software and the mean fluorescence
intensity was plotted in the graph. The P-gp activity is correlated
to Rhodamine-123 fluorescence intensity [11].
Statistical Analysis
All experiments were performed in triplicate and results were
shown in the graphs as means 6 S.E.M. Soluble lysates were
matched for protein content and analyzed by Western blotting.
Analysis of immunoblotting band density was performed by Scion
ImageH software (Frederick, MD, USA). All bands were compared
with their respective internal control. Differences were analyzed
using a one-way analysis of variance (ANOVA) followed by
Bonferoni posttest. p values, 0.05 were considered significant. All
data were analyzed using GraphPad Prism Software, Version 5.0.
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Results
LMW-PTP is Highly Expressed and Active in Resistant
Leukemia Cells
Initially, we verified the leukemia resistance model by checking
P-gp expression in K562 and its resistant counterpart Lucena-1
cells. As shown in Figure 1A, Lucena-1 cells highly express P-gp,
indicating that this cell line is an adequate model to study
intracellular resistance mediators that might contribute to
maintaining the resistant phenotype.
Subsequently, we analyzed the expression levels of LMW-PTP
and its activity in both cell lines, K562 and Lucena-1. Figure 1A
shows the overexpression of LMW-PTP in Lucena-1 cells when
compared to K562 cells. Figure 1B shows that Lucena-1 cells
present high LMW-PTP activity, about 7-fold higher than in
K562.
Overexpression of LMW-PTP in K562 Cells Decreases
Sensitivity towards Vincristine
In order to provide more information about the possible
involvement of LMW-PTP on resistant phenotype maintenance,
we overexpressed LMW-PTP through transient transfection in
K562 cells (Figure 2A) and subsequently treated these cells with
VCR. Interestingly, VCR reduced cell viability of K562 wild type
cells (K562WT) to 37,8% (61,7) while in K562 overexpressed
LMW-PTP (K562LMW-PTP) treated with VCR the cell viability
was 74,6% (611,6) compared to their respective non-treated cells
(Figure 2). Thus, it is clear that overexpression of LMW-PTP
protected the K562 cells against cell death induced by VCR.
These results strongly suggest that LMW-PTP is involved in
chemoresistance and its overexpression makes the cells more
resistant.
LMW-PTP Silencing Increases Lucena-1 Cells Sensitivity
towards Vincristine and Imatinib
To confirm the role of LMW-PTP in chemoresistance, Lucena-
1 cells were treated with VCR or imatinib mesylate (GleevecH) for
24 h after LMW-PTP silencing. Figure 3A shows the efficiency of
knocking down LMW-PTP in Lucena-1 cells. Figure 3B shows
that Lucena-1 cells become more sensitive to both drugs when
LMW-PTP is knocked down. In this experiment we set the
scramble siRNA transfected cells as 100% of viability, to allow
comparison to LMW-PTP siRNA transfected cells. Only the
transfection of LMW-PTP siRNA in Lucena-1 cells displayed
a minor effect of decreasing cell viability to approximately 80%.
Imatinib 500 nM decreased cell viability to 43.6 (67.3) in LMW-
PTP knocked down Lucena-1 cells. VCR 500 nM decreased the
number of viable cells to 22.9% (64.2). In addition, the induction
of apoptosis was also addressed by examining the activity of
caspase 3. As shown in Figure 3, an expressive increase of caspase
3 activity was observed in silenced Lucena-1 cells treated with
imatinib or VCR. It is important to mention that VCR and
imatinib displayed a slight effect on Lucena-1 wild type viability,
reduction of only 10% and 30% of cell viability, respectively (data
not shown). These results emphasize the role of LMW-PTP in
CML chemotherapy resistance.
LMW-PTP does not Affect P-gp Activity
Since LMW-PTP silencing in Lucena-1 cells made them more
sensitive to chemotherapeutic, we hypothesized that this phospha-
tase can interfere with P-gp activity. In Figure 4 we showed the
mean fluorescence intensity of Rhodamine 123 in live-gated
Lucena-1 cells after LMW-PTP silencing. The P-gp activity is
correlated with Rhodamine 123 fluorescence intensity: more
fluorescence intensity indicates less P-gp activity, while lower
fluorescence intensity indicates higher P-gp activity. In Figure 4 we
observed that the mean fluorescence intensity in LMW-PTP
knocked down Lucena-1 cells had no changes compared to
Figure 1. P-glycoprotein and LMW-PTP on both leukemia cell lines. Cells (100.000/ mL) were plated and lysed after 24 h. (A) The expression
of P-gp and LMW-PTP were evaluated by immunoblotting. Soluble lysates were matched for protein content and analyzed by Western blot and b-
actin was used as an internal control. (B) LMW-PTP from K562 and Lucena-1 cells was immunoprecipitated and afterwards had its activity determined
by using p-nitrophenyl phosphate as a substrate.
doi:10.1371/journal.pone.0044312.g001
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scramble siRNA transfected cells. As a positive control, we used
verapamil 5 mM, an inhibitor of P-gp. Thus, silencing LMW-PTP
presented no change in P-gp function. This result suggests that the
role of LMW-PTP in chemoresistance is related to another
molecular mechanism instead of directly regulating P-gp activity.
LMW-PTP is Upregulated by Vincristine Treatment in
Lucena-1 Cells
To get more evidence about the role of LMW-PTP in
chemotherapy resistance, we checked the expression of LMW-
PTP, Src and FAK in K562 and Lucena-1 cell lines treated with
VCR. Interestingly, VCR induced high expression of LMW-PTP
in Lucena-1 cells but not in K562 (Figures 5A and 5B). Src
expression and phosphorylation at Y416, its stimulatory residue,
were downregulated by VCR treatment in both leukemic cells.
Importantly, the phosphorylation (Y576 and Y577) levels of FAK
remained unchanged in K562 cells, while a decrease was observed
in Lucena-1 cells (Figure 5B). The total levels of Src decreased by
VCR treatment in both cell lines, but FAK had a slight increase in
K562 cells. These results indicate that VCR treatment interferes
with Src activity.
Figure 2. K562 cells overexpressing LMW-PTP are less sensitive towards vincristine. (A) LMW-PTP was overexpressed in K562 and its
expression was examined in the total lysate of leukemia cells. (B) K562 cells overexpression LMW-PTP (K562LMW-PTP) or not (K562WT) were treated with
VCR 125 nM for 24 h and the viable cells were counted. Each value represents the mean 6 S.D. of three independent experiments (n = 3).
***p,0.001, *p,0.5 - significant differences relative to control (no VCR) or as indicated in the graph.
doi:10.1371/journal.pone.0044312.g002
Figure 3. LMW-PTP silencing increases the cytotoxicity effect of chemotherapeutics on Lucena-1 cells. (A) LWM-PTP was knocked down
in Lucena-1 cells and its expression was checked by Western (B) After 48 h of LMW-PTP silencing Lucena-1 cells (100.000 cells/ml) were treated with
VCR 500 nM or imatinib 500 nM for 24 h, subsequently, the viable cells were assessed by trypan blue exclusion and (C) apoptosis induction by
caspase 3 activity. Each value represents the mean 6 S.E.M. of three independent experiments (n = 3) and has been normalized to scramble siRNA
sample. *** p,0.001 - significant differences relative to its respective scramble siRNA sample.
doi:10.1371/journal.pone.0044312.g003
Figure 4. Evaluation of P-glycoprotein activity. To measure P-gp
activity the substrate Rhodamine 123 was used as substrate. LMW-PTP
was silenced and after 24 h cells were further incubated for 1 h in the
presence of 200 ng/mL Rhodamine 123 with or without a P-gp inhibitor
(5 mM verapamil). Afterwards, cells were washed with PBS and
Rhodamine 123 mean fluorescence intensity was assessed by flow
cytometry analysis within the live-gate, using a FACScalibur (Becton and
Dickinson, USA). Decreasing of mean fluorescence intensity indicates
higher P-gp activity.
doi:10.1371/journal.pone.0044312.g004
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Knocking Down LMW-PTP Decreases Phosphorylation of
Src and Abl
To further investigate the molecular mechanism by which
LMW-PTP increases chemoresistance in CML, we analyzed the
levels of phospho-Src and phospho-ABL after knocking down
LMW-PTP in K562 and Lucena-1 cells. In Figure 6A we observed
that phosphorylation of Src at Tyr 416 was decreased in K562 and
Lucena-1 cells after LMW-PTP knockdown. The same was
observed for p-Bcr-ABL and p-c-Abl in Figure 6A: phosphoryla-
tion at Thr 735 residue from single c-Abl (135 kDa) and Brc-Abl
(210 kDa) was decreased by LMW-PTP silencing in both cell lines.
Figure 6B shows the densitometry analysis of the bands (p-c-Abl
and p-Bcr-Abl) obtained in Western blotting assay, normalized by
GAPDH.
Discussion
Improving chemotherapy for neoplastic diseases constitutes one
of the most important challenges in biomedical research. Among
the major issues when dealing with leukemic disease is the build-up
of resistance against therapy [13], [14]. This may include
resistance associated with decreased drug accumulation in the
cell, altered intracellular drug distribution, increased detoxifica-
tion, diminished drug-target interaction, increased DNA repair,
altered cell-cycle regulation and uncoupling of pathways linking
cellular damage with programmed cell death [13], [14]. Suppres-
sion of tumorigenesis often involves modulation of signal trans-
duction pathways, leading to modulation of gene expression, cell
cycle progression or apoptosis.
This study shows for the first time that LMW-PTP is involved in
chemoresistance. Firstly, the resistant cell line, Lucena-1, presents
high activity and expression of LMW-PTP compared to the non-
resistant cells, K562. Secondly, LMW-PTP overexpression leads to
resistant phenotype in non-resistant cells and its silencing induces
chemotherapy sensitivity in resistant cells, as clearly indicated by
apoptosis induction in those cells. LMW-PTP has already been
recognized as a possible positive mediator in tumor onset and
progression. In different tumor types the overexpression of this
phosphatase is generally a prognosis for more aggressive cancer
development [15], [5], [4]. Thus, this study contributes to
elucidate one more role of LMW-PTP in tumor progression.
We hypothesized that LMW-PTP can act directly on P-gp.
However, it was refuted because knocking down LMW-PTP in
Lucena-1 cells did not change P-gp function. This result led us to
focus on the molecular mechanism of chemoresistance. Protein
phosphorylation is a post-translational modification that can
inhibit or activate a particular protein. Since cancer cells usually
present upregulation of kinases, such as the non-receptor tyrosine
kinases, focal adhesion kinase FAK [16] and Src [17], and these
kinases are regulated by multiple phosphorylation events, we
focused our study on those kinases. Importantly, our findings
suggest that LMW-PTP contributes for Lucena-1 resistance by
maintaining the activation of Src and Bcr-Abl.
VCR treatment leads to overexpression of LMW-PTP in
Lucena -1 cells, suggesting a cellular response to counterbalance
the death-inducing stimuli. On the other hand, VCR down-
regulates FAK and Src. FAK is located in focal adhesions and
coordinates signals from integrins, cytokines, growth factor
receptors and oncogenes, playing an important role in cell motility
and survival through extracellular signal-regulated kinase (ERK),
PI3K/Akt, MAPK and JAK/STAT signaling pathways [18].
FAK has been shown to be elevated in a variety of cancers and
frequently correlates to poor patient prognosis [16]. Besides,
modulation of FAK expression and (or) phosphorylation influences
the sensitivity of tumor cells to diverse chemotherapeutic agents
[16].
Silencing LMW-PTP in Lucena-1 cells downregulated Src
(Figure 6). Src kinase family proteins are expressed in hematopoi-
etic cells and are involved in signaling pathways that regulate cell
growth and proliferation [19], [20]. Src can be activated by
cytoplasmic proteins such as, FAK or its molecular partner Crk-
associated substrate (CAS). Elevated Src activity may be caused by
increased expression or by deregulation due to overexpression of
its upstream mediators such as FAK, PDGFR, FGFR, integrin
and VEGFR [21]. In multiple tumors, overexpression and
activation of both c-Src and FAK have been demonstrated to
lead to increased invasive and metastatic potential [22]. Houan-
wen and coauthors (2009) showed that nilotinib-resistant K562
cells present up-regulation of the Src family kinase, p53/56 Lyn,
and silencing of p53/56 Lyn by siRNA in nilotinib-resistant K562
cells restored their sensitivity to nilotinib [16].
Figure 5. Expression of LMW-PTP and modulation of c-Src and FAK in leukemia cells treated with vincristine. Cells were treated with
VCR for 24 h and LMW-PTP expression, phosphorylation status of c-Src and FAK were analyzed. (A) K562 and Lucena-1 cells were treated with VCR for
24 h and the protein levels were analyzed by Western blotting. (B) The ratio between LMW-PTP/GAPDH, Src/GAPDH, FAK/GAPDH, p-Src/Src, p-FAK/
FAK from VCR treatment samples were quantified by densitometry and plot in the graph.
doi:10.1371/journal.pone.0044312.g005
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CML cells, such as K562 and Lucena-1, are characterized by
the presence of the Philadelphia chromosome translocation that
contains the BCR-ABL hybrid gene, which encodes an oncogenic
fusion protein Bcr-Abl. This fusion protein displays deregulated
protein tyrosine kinase activity that is responsible for leukemo-
genesis in vitro and in vivo [23]. For this reason, Bcr-Abl has been
considered as a target for the therapy of CML and BCR-ABL-
positive ALL [17]. In this study we demonstrated that LMW-PTP
knockdown in CML cells decreased Abl phosphorylation levels at
its activating site. This finding brings more evidence to our
hypothesis that this phosphatase might contribute for both CML
cell survival and resistance.
In conclusion, this study contributes to elucidate the role of
LMW-PTP in leukemia aggressiveness, showing for the first time
that LMW-PTP is involved in resistance, through maintaining
both Src and Bcr-Abl kinases in a more active status. However,
this mechanism is not completely elucidated and needs further
studies.
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